CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 136 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 12.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,200 | -37.9% | 930,100 | -17.1% | 0.00% | -33.3% |
| Q2 2023 | $1,931 | +50.4% | 1,122,400 | +32.0% | 0.00% | +50.0% |
| Q1 2023 | $1,284 | -40.1% | 850,300 | -36.6% | 0.00% | -33.3% |
| Q4 2022 | $2,145 | -99.9% | 1,340,774 | -25.7% | 0.00% | -25.0% |
| Q3 2022 | $2,618,000 | -1.6% | 1,805,600 | +24.2% | 0.00% | +33.3% |
| Q2 2022 | $2,661,000 | +11.2% | 1,454,261 | +62.3% | 0.00% | 0.0% |
| Q1 2022 | $2,392,000 | +9.3% | 895,900 | +77.2% | 0.00% | 0.0% |
| Q4 2021 | $2,189,000 | -51.9% | 505,500 | -43.5% | 0.00% | -50.0% |
| Q3 2021 | $4,554,000 | -29.9% | 894,600 | -12.8% | 0.01% | -25.0% |
| Q2 2021 | $6,496,000 | -42.1% | 1,026,200 | -29.4% | 0.01% | -42.9% |
| Q1 2021 | $11,228,000 | -17.0% | 1,452,568 | -29.6% | 0.01% | -6.7% |
| Q4 2020 | $13,522,000 | -11.8% | 2,064,500 | -10.4% | 0.02% | 0.0% |
| Q3 2020 | $15,326,000 | -21.7% | 2,304,600 | -2.0% | 0.02% | -11.8% |
| Q2 2020 | $19,581,000 | +15.6% | 2,350,671 | +6.5% | 0.02% | +6.2% |
| Q1 2020 | $16,935,000 | -1.2% | 2,208,000 | +7.0% | 0.02% | +23.1% |
| Q4 2019 | $17,146,000 | +51.6% | 2,063,271 | +34.7% | 0.01% | +30.0% |
| Q3 2019 | $11,308,000 | -28.4% | 1,532,300 | +8.9% | 0.01% | -28.6% |
| Q2 2019 | $15,787,000 | +13.8% | 1,407,000 | +9.0% | 0.01% | +7.7% |
| Q1 2019 | $13,874,000 | -30.3% | 1,290,600 | -2.1% | 0.01% | -40.9% |
| Q4 2018 | $19,899,000 | -29.3% | 1,317,800 | -13.3% | 0.02% | -24.1% |
| Q3 2018 | $28,129,000 | -52.8% | 1,520,500 | -35.9% | 0.03% | -12.1% |
| Q2 2018 | $59,613,000 | +118.0% | 2,372,700 | +146.8% | 0.03% | +10.0% |
| Q1 2018 | $27,346,000 | +81.1% | 961,200 | +34.4% | 0.03% | +76.5% |
| Q4 2017 | $15,096,000 | +54.5% | 715,100 | +32.9% | 0.02% | +41.7% |
| Q3 2017 | $9,774,000 | +53.5% | 537,900 | +30.9% | 0.01% | +50.0% |
| Q2 2017 | $6,369,000 | +57.1% | 410,900 | +75.0% | 0.01% | +33.3% |
| Q1 2017 | $4,055,000 | +304.7% | 234,800 | +157.5% | 0.01% | +200.0% |
| Q4 2016 | $1,002,000 | – | 91,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,576,471 | $43,106,000 | 1.62% |
| Altium Capital Management LP | 483,041 | $3,734,000 | 1.04% |
| RA Capital Management | 3,500,000 | $27,055,000 | 0.41% |
| Point72 Asset Management, L.P. | 6,335,000 | $48,970,000 | 0.23% |
| Perceptive Advisors | 2,153,974 | $16,650,000 | 0.21% |
| RTW INVESTMENTS, LP | 1,533,758 | $11,856,000 | 0.18% |
| GLOBEFLEX CAPITAL L P | 115,647 | $894,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 785,899 | $6,075,000 | 0.14% |
| Affinity Asset Advisors, LLC | 50,000 | $387,000 | 0.13% |
| Virtus ETF Advisers LLC | 38,021 | $294,000 | 0.12% |